AbCellera Biologics News

This is selected news for AbCellera Biologics, which is filed under Sectors / Healthtech. There are 776 news items for this page. AbCellera Biologics is occasionally combined with Leerink Partners, Carl Hansen and Kevin Heyries in news items. A press release filter page is also available for AbCellera Biologics.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/1/2022 Health Care Sector Update for 12/01/2022: OFIX, NTLA, ABCL, XLV, IBB
... value after it priced an underwritten public offering of 6.6 million common shares at $45.80 per share for expected gross proceeds of about $300 million. AbCellera Biologics (ABCL) was up more than 1% after the company and Rallybio (RLYB) announced a strategic collaboration to develop and commercialize antibody-based therapeutics ...
Nasdaq
11/30/2022 Patent, partnership court fight looms for biotech
By all accounts, AbCellera Biologics Inc. (Nasdaq:ABCL) has been nothing short of a made-in-Vancouver success story, leapfrogging from the research labs of the University of British Columbia (UBC) onto the Nasdaq in December 2020 with an initial public offering of US$555.5 million ‚Ai a record for ...
biv.com
11/30/2022 ABCL Stock: How This Pullback Could Offer A New Buying Opportunity
AbCellera Biologics AbCellera Biologics ABCL $0.20 1.47% 37% IBD Stock Analysis - Stock briefly broke out of cup base on Nov. 14, then retreated - Shares created a high handle for cup base, offering a new entry - Relative Strength Rating is 97 out of 99; Composite Rating is 94 Industry Group Ranking ...
bitcoinethereumnews.com
11/30/2022 IBD Stock Of The Day AbCellera Is Pulling Back
AbCellera Biologics AbCellera Biologics ABCL - Stock briefly broke out of cup base on Nov. 14, then retreated - Shares created a high handle for cup base, offering a new entry - Relative Strength Rating is 97 out of 99; Composite Rating is 94 Industry Group Ranking Emerging Pattern Cup with Handle A ...
biztoc.com
11/29/2022 How A Brief Pullback Could Actually Be A Buying Opportunity For This Stock Of The Day
AbCellera Biologics AbCellera Biologics ABCL $0.13 0.92% 47% ibd stock analysis - The stock briefly broke out of the cup base on November 14, then retraced. - The shares made a higher handle towards the cup base, offering a fresh entry - Relative strength rating is 97 out of 99; overall rating is ...
latestfinance.news
11/19/2022 Analyzing AbCellera Biologics (NASDAQ:ABCL) and MusclePharm (OTCMKTS:MSLP) - The Cerbat Gem
AbCellera Biologics ( NASDAQ:ABCL ‚Ai Get Rating ) and MusclePharm ( OTCMKTS:MSLP ‚Ai Get Rating ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends. Earnings and Valuation This ...
thecerbatgem.com
11/19/2022 MusclePharm (OTCMKTS:MSLP) and AbCellera Biologics (NASDAQ:ABCL) Head to Head Contrast - WKRB News
MusclePharm ( OTCMKTS:MSLP ‚Ai Get Rating ) and AbCellera Biologics ( NASDAQ:ABCL ‚Ai Get Rating ) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability. Analyst Ratings This ...
wkrb13.com
11/17/2022 Critical Survey: AbCellera Biologics (NASDAQ:ABCL) versus MusclePharm (OTCMKTS:MSLP) - Watch List News
AbCellera Biologics ( NASDAQ:ABCL ‚Ai Get Rating ) and MusclePharm ( OTCMKTS:MSLP ‚Ai Get Rating ) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Risk & Volatility AbCellera Biologics ...
watchlistnews.com
11/17/2022 Critical Survey: AbCellera Biologics (NASDAQ:ABCL) versus MusclePharm (OTCMKTS:MSLP)
AbCellera Biologics (NASDAQ:ABCL ‚Ai Get Rating) and MusclePharm (OTCMKTS:MSLP ‚Ai Get Rating) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Risk & Volatility AbCellera Biologics ...
dispatchtribunal.com
11/16/2022 First Look Analyst Calls Briefing for Wednesday, November 16, 2022
... MMP) downgraded to Underperform from Peer Perform at Wolfe Research; tgt $49 Rapid7 (RPD) downgraded to Sector Weight from Overweight at KeyBanc Capital Markets Others: AbCellera Biologics (ABCL) initiated with a Buy at Truist; tgt $29 MindMed (MNMD) initiated with an Outperform at RBC Capital Mkts; tgt $5 Sponsored: Tips ...
247wallst.com
11/16/2022 Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2022 - Advance Auto Parts (NYSE:AAP), AbCellera Biologics (NASDAQ:ABCL)
... and a 52-week-low of $18.89. At the end of the last trading period, Lithium Americas closed at $26.39. Truist Securities initiated coverage on AbCellera Biologics Inc ABCL with a Buy rating. The price target for AbCellera Biologics is set to $29.00. AbCellera Biologics earned $0.08 in the third ...
Benzinga
11/15/2022 MusclePharm (OTCMKTS:MSLP) and AbCellera Biologics (NASDAQ:ABCL) Head to Head Survey - Ticker Report
MusclePharm ( OTCMKTS:MSLP ‚Ai Get Rating ) and AbCellera Biologics ( NASDAQ:ABCL ‚Ai Get Rating ) are both consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings. Insider & Institutional Ownership ...
Ticker Report
11/12/2022 AbCellera Biologics (NASDAQ:ABCL) & MusclePharm (OTCMKTS:MSLP) Financial Contrast
AbCellera Biologics (NASDAQ:ABCL ‚Ai Get Rating) and MusclePharm (OTCMKTS:MSLP ‚Ai Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Valuation and Earnings This ...
defenseworld.net
11/11/2022 Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday - Apple (NASDAQ:AAPL), AbCellera Biologics (NASDAQ:ABCL) - Benzinga
... jumped 10% to close at $27.50 after dropping 8% on Wednesday. CleanSpark, Inc. CLSK rose 9.5% to close at $2.72 after dropping 15% on Wednesday. AbCellera Biologics Inc. ABCL rose 9.3% to close at $12.91 after the company reported better-than-expected Q3 results. Apple Inc. AAPL jumped 8.9% to ...
Benzinga
11/10/2022 Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session - Apple (NASDAQ:AAPL), AbCellera Biologics (NASDAQ:ABCL) - Benzinga
... a rise in jobless claims. This has alleviated some concerns of high inflation and a tight labor market. Microsoft Corporation MSFT rose 6.2% to $238.32. AbCellera Biologics Inc. ABCL rose 4.4% to $12.33 after the company reported better-than-expected Q3 results. Losers Apyx Medical Corporation APYX shares dipped 63.2 ...
Benzinga
11/9/2022 Equities Research Analysts’ Price Target Changes for November 9th (ABCL, ABF, ACEL, ACRDF, ADCT, ADS, AEL, AES, AEVA, AFRM)
Equities Research Analysts‚Ao price target changes for Wednesday, November 9th: AbCellera Biologics (NASDAQ:ABCL) had its target price increased by SVB Leerink LLC from $13.00 to $20.00. The firm currently has an outperform rating on the stock. Associated British Foods (LON:ABF) had its price target boosted by Barclays ...
theenterpriseleader.com
11/9/2022 Why Array Technologies Shares Are Trading Sharply Higher; Here Are 28 Stocks Moving Premarket - AbCellera Biologics (NASDAQ:ABCL), Affirm Holdings (NASDAQ:AFRM) - Benzinga
... trading after the company reported a narrower Q3 loss. Akerna Corp. KERN rose 8.1% to $1.48 in pre-market trading after dropping 13% on Tuesday. AbCellera Biologics Inc. ABCL rose 7.5% to $13.16 in pre-market trading after the company reported better-than-expected Q3 results. Korea Electric Power Corporation ...
Benzinga
11/9/2022 AbCellera Biologics (NASDAQ:ABCL) PT Raised to $20.00
AbCellera Biologics (NASDAQ:ABCL ‚Ai Get Rating) had its target price lifted by investment analysts at SVB Leerink from $13.00 to $20.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has an ‚Auoutperform‚Au rating on the stock. SVB Leerink's price target would suggest a ...
modernreaders.com
11/4/2022 AbCellera to Present at Upcoming Investor Conferences in November | Business | The Daily News
... links that will be posted on AbCellera's Investor Relations website . Replays of each webcast will be available through the same links following the presentations. About AbCellera Biologics Inc . AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into ...
galvnews.com
11/4/2022 Eli Lilly COVID-19 therapy unlikely to neutralize new Omicron subvariants - FDA
... injection Veklury from Gilead (GILD), are expected to retain efficacy against circulating COVID variants including BQ.1 and BQ.1.1, the FDA added. - Discovered by AbCellera Biologics (NASDAQ:ABCL), bebtelovimab is a monoclonal antibody licensed and developed by Eli Lilly (LLY). - According to estimates from the Centers for Disease Control ...
Seeking Alpha
11/2/2022 AbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $21.00 by Analysts at Piper Sandler
AbCellera Biologics (NASDAQ:ABCL ‚Ai Get Rating) had its price objective trimmed by Piper Sandler from $22.00 to $21.00 in a research report released on Tuesday morning, The Fly reports. Separately, Credit Suisse Group decreased their price objective on shares of AbCellera Biologics from $40.00 to $34.00 and set an ...
defenseworld.net
11/2/2022 AbCellera Biologics Inc. (NASDAQ:ABCL) Position Lessened by DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale reduced its holdings in AbCellera Biologics Inc. ( NASDAQ:ABCL ‚Ai Get Rating ) by 53.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 87,000 shares of the company's stock after selling 100,000 ...
American Banking News
11/2/2022 2022-11-02 | NDAQ:ABCL | Press Release | AbCellera Biologics Inc.
... royalties on net sales of products. AbCellera received a milestone payment for this antibody candidate and the amount of the payment was not disclosed. About AbCellera Biologics Inc. AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into ...
stockhouse.com
11/1/2022 Research Analysts’ Price Target Changes for November 1st (AANNF, AB, ABCL, ABR, ADOIF, AFL, AGFY, AMBP, AMED, AMT) - Mayfield Recorder
... AB) had its price target increased by The Goldman Sachs Group, Inc. from $36.00 to $41.00. They currently have a neutral rating on the stock. AbCellera Biologics (NASDAQ:ABCL) had its target price reduced by Piper Sandler from $22.00 to $21.00. Arbor Realty Trust (NYSE:ABR) had its price target ...
Mayfield Recorder
11/1/2022 Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insmed (INSM), AbbVie (ABBV) and Teladoc (TDOC) | Markets Insider
... star analyst with an average return of 15.4% and a 46.0% success rate. Willey covers the Healthcare sector, focusing on stocks such as Bolt Biotherapeutics, AbCellera Biologics, and SQZ Biotechnologies. Insmed has an analyst consensus of Strong Buy, with a price target consensus of $45.29, a 156.0% upside from current ...
Business Insider